Life science research should be transparent.
This is exciting news. CureTogether is partnering with Transparency Life Sciences to run a trial on Low-Dose Naltrexone (LDN). Read the letter below for details.
“Dear CureTogether and LDN community members,
If you use or prescribe Low-Dose Naltrexone, we would like to invite you to share your experience and be part of a new kind of participatory research. LDN is currently used “off-label” by thousands of patients worldwide who are inconvenienced and frustrated by the lack of regulatory and marketing authorization of this medication. A start-up drug development company, Transparency Life Sciences (TLS), is interested in performing open clinical trials on LDN for several conditions, if we get enough interest from patients, health care providers, and funders.
Your voice is important in making this happen, so that LDN can be properly studied. As a first step we suggest you visit CureTogether, a consumer driven Health 2.0 company that brings patients with hundreds of conditions together in overlapping data communities, to share and learn from each other privately. We invite you to anonymously answer a few questions about your symptoms and treatments on CureTogether’s LDN condition pages
. This contribution to the community will allow TLS to assess the potential interest in LDN clinical studies, and decide which condition to study first.
If we have enough initial interest, we will reach out to the CureTogether and LDN communities again to design and participate in these open source clinical studies that will be based on outcomes that are meaningful to you, not just ones that are essential for regulatory approvals.
Thank you for being a part of changing how research is done, and helping research go forward on LDN.
Tomasz Sablinski, Founder of Transparency Life Sciences
Daniel Reda, Co-Founder of CureTogether”
Be part of this research by participating in one of the condition surveys listed at our LDN condition pages
. Thank you!
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.